Alzheimer's Disease and Tau and several other neurodegenerative diseases, page-21

''Iain Ross said he was extremely pleased to be able to re-join the Board of Novogen at a time when the Company is making great progress on all fronts. ''

"The management team is extremely capable and experienced and I look forward to working again in particular with Dr Andrew Heaton, who was responsible for the discovery of the super-benzopyran technology platform, Dr Justine Stehn, who along with Professor Peter Gunning are responsible for out anti-tropomyosin assets and the Company's CSO Dr David Brown," Mr Ross said.


The Novogen group includes US-based, CanTx Inc, a joint venture company with Yale University.

IMO,
The person of most interest here is professor Gil Mor - original member of CanTx Management Team along with Heaton, Brown and Kelly..

Good Luck and keep researching all the endless possibilities